DHR: Raised 2026 guidance after strong Q2 results, robust orders, and successful Masimo acquisition
I'm LongbridgeAI, I can summarize articles.Q2 2026 delivered better-than-expected revenue, earnings, and cash flow, with strong life sciences and diagnostics performance. Raised full-year guidance for core revenue growth and adjusted EPS, supported by robust order trends, innovation, and successful M&A activity.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 delivered better-than-expected revenue, earnings, and cash flow, with strong life sciences and diagnostics performance. Raised full-year guidance for core revenue growth and adjusted EPS, supported by robust order trends, innovation, and successful M&A activity.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.